{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:18:36Z","timestamp":1790651916734,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.euroneuro.2023.04.008","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T05:07:45Z","timestamp":1681708065000},"page":"24-35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["The impact of the COVID-19 pandemic on ADHD medicine consumption in 47 countries and regions"],"prefix":"10.1016","volume":"73","author":[{"given":"Sophie","family":"Gimbach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6360-4077","authenticated-orcid":false,"given":"Daniel","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Fried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen V.","family":"Faraone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4595-1144","authenticated-orcid":false,"given":"Tobias","family":"Banaschewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Buitelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7929-0463","authenticated-orcid":false,"given":"Manfred","family":"D\u00f6pfner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Ammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2023.04.008_bib0001","series-title":"Diagnostic and Statistical Manual of Mental Disorders. 5th ed","year":"2013"},{"issue":"10228","key":"10.1016\/j.euroneuro.2023.04.008_bib0002","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S0140-6736(20)30567-5","article-title":"How will country-based mitigation measures influence the course of the COVID-19 epidemic?","volume":"395","author":"Anderson","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.euroneuro.2023.04.008_bib0003","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.euroneuro.2017.03.002","article-title":"Trends in ADHD medication use in children and adolescents in five western countries, 2005\u20132012","volume":"27","author":"Bachmann","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"7","key":"10.1016\/j.euroneuro.2023.04.008_bib0004","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1177\/10870547211050945","article-title":"Systematic review: investigating the impact of COVID-19 on mental health outcomes of individuals with ADHD","volume":"26","author":"Behrmann","year":"2022","journal-title":"J. Atten. Disord."},{"issue":"2","key":"10.1016\/j.euroneuro.2023.04.008_bib0005","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1001\/jamapsychiatry.2022.4165","article-title":"Pschotropic medication use and psychiatric disorders during the covid-19 pandemic among danish children, adolescents, and young adults","volume":"80","author":"Bliddal","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1016\/j.euroneuro.2023.04.008_bib0006","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/0269881113519509","article-title":"Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the british association for psychopharmacology","volume":"28","author":"Bolea-Alama\u00f1ac","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.04.008_bib0007","series-title":"Introduction to Time Series and Forecasting. Springer Texts in Statistics","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-29854-2","author":"Brockwell","year":"2016"},{"issue":"9","key":"10.1016\/j.euroneuro.2023.04.008_bib0008","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1001\/jamapsychiatry.2016.1182","article-title":"Trends in stimulant medication use in commercially insured youths and adults, 2010-2014","volume":"73","author":"Burcu","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.04.008_bib0010","series-title":"Prevention and Control of COVID-19","year":"2022"},{"key":"10.1016\/j.euroneuro.2023.04.008_bib0011","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2015.20","article-title":"Attention-deficit\/hyperactivity disorder","volume":"1","author":"Faraone","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.euroneuro.2023.04.008_bib0012","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.neubiorev.2021.01.022","article-title":"The world federation of ADHD international consensus statement: 208 evidence-based conclusions about the disorder","volume":"128","author":"Faraone","year":"2021","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"2","key":"10.1016\/j.euroneuro.2023.04.008_bib0013","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1017\/S003329170500471X","article-title":"The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies","volume":"36","author":"Faraone","year":"2006","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2023.04.008_bib0014","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jaac.2019.06.012","article-title":"Systematic review: nonmedical use of prescription stimulants: risk factors, outcomes, and risk reduction strategies","volume":"59","author":"Faraone","year":"2020","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.04.008_bib0015","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.euroneuro.2022.10.004","article-title":"Psychotropic drug repurposing for COVID-19: a systematic review and meta-analysis","volume":"66","author":"Fico","year":"2022","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"5","key":"10.1016\/j.euroneuro.2023.04.008_bib0016","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/occmed\/kqaa093","article-title":"Sickness absence in healthcare workers during the COVID-19 pandemic","volume":"70","author":"Gohar","year":"2020","journal-title":"Occup. Med."},{"issue":"5","key":"10.1016\/j.euroneuro.2023.04.008_bib0017","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1176\/ps.62.5.pss6205_0459","article-title":"International variation in treatment procedures for ADHD: social context and recent trends","volume":"62","author":"Hinshaw","year":"2011","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.euroneuro.2023.04.008_bib0018","series-title":"World Economic Outlook, April 2020: The great Lockdown","year":"2020"},{"issue":"19","key":"10.1016\/j.euroneuro.2023.04.008_bib0019","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12402-014-0142-1","article-title":"Comorbid mental disorders in children and adolescents with attention-deficit\/hyperactivity disorder in a large nationwide study","volume":"7","author":"Jensen","year":"2015","journal-title":"Atten. Defic. Hyperact. Disord."},{"key":"10.1016\/j.euroneuro.2023.04.008_bib0020","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s00228-016-2125-y","article-title":"Use of drugs for ADHD among adults\u2014A multinational study among 15.8 million adults in the nordic countries","volume":"72","author":"Karlstad","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.euroneuro.2023.04.008_bib0021","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.eurpsy.2018.11.001","article-title":"Updated European Consensus Statement on diagnosis and treatment of adult ADHD","volume":"56","author":"Kooij","year":"2019","journal-title":"Eur. Psychiatry"},{"issue":"4","key":"10.1016\/j.euroneuro.2023.04.008_bib0022","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/acps.13483","article-title":"Psychotropic medication use in pediatric population during COVID-19 pandemic","volume":"146","author":"Kuitunen","year":"2022","journal-title":"Acta Psychiatr. Scand."},{"issue":"3","key":"10.1016\/j.euroneuro.2023.04.008_bib0023","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1001\/jamapediatrics.2021.5634","article-title":"Psychotropic drug use in children and adolescents before and during the COVID-19 pandemic","volume":"176","author":"Leong","year":"2022","journal-title":"JAMA Pediatr."},{"issue":"565098","key":"10.1016\/j.euroneuro.2023.04.008_bib0024","article-title":"A systematic review of the impact of viral respiratory epidemics on mental health: an implication on the coronavirus disease 2019 pandemic","volume":"11","author":"Luo","year":"2020","journal-title":"Front. Psychiatry"},{"issue":"14","key":"10.1016\/j.euroneuro.2023.04.008_bib0025","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1177\/1087054714536047","article-title":"ADHD drug prescribing trend is increasing among children and adolescents in Hong Kong","volume":"21","author":"Man","year":"2017","journal-title":"J. Atten. Disord."},{"key":"10.1016\/j.euroneuro.2023.04.008_bib0026","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.euroneuro.2021.10.864","article-title":"The impact of the prolonged COVID-19 pandemic on stress resilience and mental health: a critical review across waves","volume":"55","author":"Manchia","year":"2022","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.04.008_bib0027","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.euroneuro.2020.11.005","article-title":"Transciptome profiling in adult attention-deficit hyperactivity disorder","volume":"41","author":"Mortimer","year":"2020","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.04.008_bib0028","volume":"87","year":"2019"},{"issue":"2","key":"10.1016\/j.euroneuro.2023.04.008_bib0029","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/YIC.0000000000000384","article-title":"Social withdrawal as a trans-diagnostic predictor of short-term remission: a meta-analysis of five clinical cohorts","volume":"37","author":"Oliva","year":"2022","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2023.04.008_bib0030","article-title":"Behavioral impact of lockdown and quarantine measures for COVID-19 pandemic on children, adolescents and caregivers: a systematic review and meta-analysis","volume":"67","author":"Panda","year":"2021","journal-title":"J. Tropic. Pedr."},{"issue":"7","key":"10.1016\/j.euroneuro.2023.04.008_bib0031","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1097\/chi.0b013e318054e724","article-title":"Practice parameter for the assessment and treatment of children and adolescents with attention-deficit\/hyperactivity disorder","volume":"46","author":"Pliszka","year":"2007","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"6","key":"10.1016\/j.euroneuro.2023.04.008_bib0032","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1176\/ajp.2007.164.6.942","article-title":"The worldwide prevalence of ADHD: a systematic review and metaregression analysis","volume":"164","author":"Polanczyk","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.04.008_bib0033","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/ije\/dyt261","article-title":"ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis","volume":"43","author":"Polanczyk","year":"2014","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.euroneuro.2023.04.008_bib0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euroneuro.2021.01.002","article-title":"Integrating genomics and transcriptomics: towards deciphering ADHD","volume":"44","author":"Pujol-Gualdo","year":"2021","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.04.008_bib0035","series-title":"R: A Language and Environment for Statistical Computing. R Foundation For Statistical Computing, Vienna, Austria","year":"2022"},{"key":"10.1016\/j.euroneuro.2023.04.008_bib0036","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S2215-0366(18)30293-1","article-title":"Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases","volume":"5","author":"Raman","year":"2018","journal-title":"Lancet Psychiatr."},{"key":"10.1016\/j.euroneuro.2023.04.008_bib0037","series-title":"Coronavirus Pandemic (COVID-19). Our World in Data","author":"Ritchie","year":"2020"},{"issue":"10312","key":"10.1016\/j.euroneuro.2023.04.008_bib0038","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0140-6736(21)02143-7","article-title":"Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic","volume":"398","author":"Santomauro","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.euroneuro.2023.04.008_bib0039","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1177\/1087054720978549","article-title":"Physical health, media use, and mental health in children and adolescents with ADHD during the COVID-19 pandemic in Australia","volume":"26","author":"Sciberras","year":"2022","journal-title":"J. Atten. Disord."},{"key":"10.1016\/j.euroneuro.2023.04.008_bib0040","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.euroneuro.2018.06.003","article-title":"Role of conduct problems in the relation between Attention-Deficit Hyperactivity disorder, substance use, and gaming","volume":"30","author":"Schoenmacker","year":"2020","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.04.008_bib0041","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.852664","article-title":"The impact of the COVID-19 pandemic on diagnosing and treating attention deficit hyperactivity disorder: new challenges on initializing and optimizing pharmacological treatment","volume":"13","author":"Segenreich","year":"2022","journal-title":"Front. Psychiatry"},{"issue":"10","key":"10.1016\/j.euroneuro.2023.04.008_bib0042","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1177\/1087054715597410","article-title":"Variation in presentation, diagnosis, and management of children and adolescents with ADHD across european countries","volume":"22","author":"Setyawan","year":"2018","journal-title":"J. Att. Disord."},{"issue":"1","key":"10.1016\/j.euroneuro.2023.04.008_bib0043","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1055\/s-0040-1718645","article-title":"Impact of COVID-19 and lockdown on children with ADHD and their families - an online survey and a continuity care model","volume":"12","author":"Shah","year":"2021","journal-title":"J. Nerosci. Rural Pract."},{"key":"10.1016\/j.euroneuro.2023.04.008_bib0044","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1741-7015-10-99","article-title":"A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment","volume":"10","author":"Shaw","year":"2012","journal-title":"BMC Med."},{"issue":"3","key":"10.1016\/j.euroneuro.2023.04.008_bib0045","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1192\/bjp.bp.107.048827","article-title":"Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis","volume":"194","author":"Simon","year":"2009","journal-title":"Br. J. Psychiatr."},{"key":"10.1016\/j.euroneuro.2023.04.008_bib0046","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.neuropharm.2014.06.014","article-title":"The use of stimulant medications for non-core aspects of ADHD and in other disorders","volume":"87","author":"Sinita","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2023.04.008_bib0047","doi-asserted-by":"crossref","first-page":"04009","DOI":"10.7189\/jogh.11.04009","article-title":"The prevalence of adult attention-deficit hyperactivity disorder: a global systematic review and meta-analysis","volume":"11","author":"Song","year":"2021","journal-title":"Glob. Health"},{"key":"10.1016\/j.euroneuro.2023.04.008_bib0048","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euroneuro.2021.02.002","article-title":"Do effects of methylphenidate on cognitive performance last beyond treatment? A randomized placebo-controlled trial in boys and men with ADHD","volume":"46","author":"Tamminga","year":"2021","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.04.008_bib0049","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(15)00238-X","article-title":"Attention deficit hyperactivity disorder","volume":"387","author":"Thapar","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.euroneuro.2023.04.008_bib0050","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1542\/peds.2014-3482","article-title":"Prevalence of attention deficit hyperactivity disorder: a systematic review and meta-analysis","volume":"135","author":"Thomas","year":"2015","journal-title":"Pediatric"},{"key":"10.1016\/j.euroneuro.2023.04.008_bib0051","series-title":"World Population Prospects 2019","year":"2019"},{"issue":"5","key":"10.1016\/j.euroneuro.2023.04.008_bib0052","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3810\/pgm.2010.09.2206","article-title":"Understanding attention-deficit\/hyperactivity disorder form childhood to adulthood","volume":"122","author":"Wilens","year":"2010","journal-title":"Postgrad. Med."},{"issue":"4","key":"10.1016\/j.euroneuro.2023.04.008_bib0053","article-title":"Clinical Practice guideline for the diagnosis, evaluation, and treatment of attention-deficit\/hyperactivity disorder in children and adolescents [published correction appears in pediatrics. 2020, 145(3)]","volume":"144","author":"Wolraich","year":"2019","journal-title":"Pediatrics"},{"key":"10.1016\/j.euroneuro.2023.04.008_bib0054","series-title":"Mental Health and Psychosocial Considerations During the COVID-19 Outbreak","year":"2020"},{"key":"10.1016\/j.euroneuro.2023.04.008_bib0055","series-title":"COVID-19","year":"2020"},{"key":"10.1016\/j.euroneuro.2023.04.008_bib0056","series-title":"Collaborating Centre for Drug Statistics Methodology Oslo","year":"2022"},{"issue":"6","key":"10.1016\/j.euroneuro.2023.04.008_bib0057","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1089\/cap.2015.0239","article-title":"Stimulants and pediatric cardiovascular risk","volume":"27","author":"Zito","year":"2017","journal-title":"J. Child Adolesc. Psychopharmacol."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X23000755?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X23000755?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T18:05:34Z","timestamp":1760378734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X23000755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":56,"alternative-id":["S0924977X23000755"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2023.04.008","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of the COVID-19 pandemic on ADHD medicine consumption in 47 countries and regions","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2023.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}